Brief: Regulus Therapeutics Announces First Subject Dosed In Phase 1 Single-Ascending Dose Clinical Trial Of RGLS8429 For Treatment Of Autosomal Dominant Polycystic Kidney Disease
13/06/2022 13:04
June 13 (Reuters) - Regulus Therapeutics Inc RGLS.O :
* REGULUS THERAPEUTICS ANNOUNCES FIRST SUBJECT DOSED IN
PHASE 1
SINGLE-ASCENDING DOSE (SAD) CLINICAL TRIAL OF RGLS8429 FOR THE
TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
(ADPKD)
Source text for Eikon: ID:nPn9SD5rQa
Further company coverage: RGLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regulus Therapeutics
See all newsBrief: Novartis Completes Acquisition Of Regulus Therapeutics
Brief: Novartis Announces Expiration Of Hart-Scott-Rodino Waiting Period Of Regulus Therapeutics Tender Offer
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics
Regulus Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Regulus Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview